Steris

STERIS Announces Financial Results for Fiscal 2024 Third Quarter

Retrieved on: 
Wednesday, February 7, 2024
Customer, STE, Steris, Growth, Public expenditure, Video game

Third quarter revenue increases 15% as reported; 10% constant currency organic

Key Points: 
  • Third quarter revenue increases 15% as reported; 10% constant currency organic
    As reported diluted earnings per share increased to $1.42; adjusted earnings per share increased to $2.22
    DUBLIN, IRELAND, Feb. 07, 2024 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) today announced financial results for its fiscal 2024 third quarter ended December 31, 2023.
  • Constant currency organic revenue (see Non-GAAP Financial Measures) increased 10% for the third quarter of fiscal 2024 as compared to the third quarter of fiscal 2023.
  • Healthcare revenue as reported grew 19% in the quarter to $916.2 million compared with $769.1 million in the third quarter of fiscal 2023.
  • Reflecting lower volume, operating income was $18.3 million in the third quarter of fiscal 2024 compared with $20.3 million in the prior year’s third quarter.

STERIS Announces Dividend of $0.52 per share

Retrieved on: 
Tuesday, January 30, 2024
Pillar, MLI, COVID-19, Growth, Congress, Pressure, Legislation, Literature, Annual report, FDA, Marketing, CAMT, Acquisition, IRA, TCJA, Risk, Health, EPA, STE, Steris, Insurance, Income tax, Accounting

DUBLIN, IRELAND , Jan. 30, 2024 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that the Company will distribute a quarterly interim dividend of $0.52 per share.

Key Points: 
  • DUBLIN, IRELAND , Jan. 30, 2024 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that the Company will distribute a quarterly interim dividend of $0.52 per share.
  • The dividend is payable on March 22, 2024, to shareholders of record at the close of business on February 23, 2024.
  • Additional information about the U.S. tax treatment of dividends, including required Forms 8937, is available at www.steris-ir.com .
  • STERIS is a leading global provider of products and services that support patient care with an emphasis on infection prevention.

STERIS to Host a Conference Call for Fiscal 2024 Third Quarter Financial Results on February 8, 2024

Retrieved on: 
Tuesday, January 23, 2024
STE, Steris

DUBLIN, IRELAND, Jan. 23, 2024 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that it will host a conference call to discuss its fiscal 2024 third quarter financial results at 9:00 a.m.

Key Points: 
  • DUBLIN, IRELAND, Jan. 23, 2024 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that it will host a conference call to discuss its fiscal 2024 third quarter financial results at 9:00 a.m.
  • The conference call can be heard live at www.steris-ir.com or via phone by dialing 1-833-535-2199 in the United States or 1-412-902-6776 internationally, then asking to join the conference call for STERIS plc.
  • A press release detailing financial results will be issued after the U.S. market closes on February 7, 2024.
  • For those unable to listen to the conference call live, a replay will be available beginning at 12:00 p.m.

STERIS Announces Financial Results for Fiscal 2024 Second Quarter

Retrieved on: 
Tuesday, November 7, 2023
BD, Steris, Growth, Customer, NYSE, Health care, Dental, STE, AST, Video game

Constant currency organic revenue (see Non-GAAP Financial Measures) increased 8% for the second quarter of fiscal 2024 as compared to the second quarter of fiscal 2023.

Key Points: 
  • Constant currency organic revenue (see Non-GAAP Financial Measures) increased 8% for the second quarter of fiscal 2024 as compared to the second quarter of fiscal 2023.
  • Adjusted net income (see Non-GAAP Financial Measures) for the second quarter of fiscal 2024 was $202.2 million or $2.03 per diluted share, compared with the previous year’s second quarter of $199.6 million or $1.99 per diluted share.
  • Dental second quarter revenue as reported declined 5% to $104.2 million compared with $109.6 million in the second quarter of fiscal 2023.
  • Reflecting lower volume, operating income was $24.5 million in the second quarter of fiscal 2024 compared with $28.1 million in the prior year’s second quarter.

STERIS Announces Dividend of $0.52 per share

Retrieved on: 
Tuesday, October 31, 2023
Pillar, FDA, Insurance, NYSE, American Bar Association Model Rules of Professional Conduct, Literature, Pressure, IRA, CAMT, Congress, Legislation, Acquisition, Health, TCJA, EPA, Growth, Risk, COVID-19, MLI, Income tax, Marketing, Steris, Annual report, Accounting, STE, Cantel Medical Corporation, Brexit, EU

DUBLIN, IRELAND, Oct. 31, 2023 (GLOBE NEWSWIRE) --  STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that the Company will distribute a quarterly interim dividend of $0.52 per share.

Key Points: 
  • DUBLIN, IRELAND, Oct. 31, 2023 (GLOBE NEWSWIRE) --  STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that the Company will distribute a quarterly interim dividend of $0.52 per share.
  • The dividend is payable on December 21, 2023, to shareholders of record at the close of business on November 21, 2023.
  • STERIS is a leading global provider of products and services that support patient care with an emphasis on infection prevention.
  • WE HELP OUR CUSTOMERS CREATE A HEALTHIER AND SAFER WORLD by providing innovative healthcare, life sciences and dental products and services around the globe.

FDA Roundup: October 31, 2023

Retrieved on: 
Tuesday, October 31, 2023
Cream, Ice cream, FDA, Steris, Food, Ethylene oxide, Vaccine, Listeria monocytogenes, Cisplatin, Human services, Infection, News, Medical device, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, PMA, HIV disease progression rates, Cosmetics, NPC, Soft serve, Multimedia, Dietary supplement, Environment, Nasopharyngeal carcinoma, Disease, Radiation, EO, Sterilization, Public, House, Woman, Safety, Use of Free and Open-Source Software (FOSS) in the U.S. Department of Defense, Office of Inspector General, U.S. Department of Health and Human Services, Patient, Heated tobacco product, China Biologic Products, Animal, Essure

The FDA remains committed to collecting and providing updates on the long-term safety and effectiveness information about Essure, a permanently implanted birth control device for women.

Key Points: 
  • The FDA remains committed to collecting and providing updates on the long-term safety and effectiveness information about Essure, a permanently implanted birth control device for women.
  • Although Essure has not been available for implantation in the United States since December 2019, the FDA continues to monitor the product's safety through an FDA-required postmarket surveillance ("522") study and other activities.
  • The master file was submitted by Steris Corporation, Sterilization for Medical Devices | FDA .
  • The FDA also approved toripalimab-tpzi as a single agent for adults with recurrent unresectable or metastatic NPC with disease progression on or after a platinum-containing chemotherapy.

STERIS to Host a Conference Call for Fiscal 2024 Second Quarter Financial Results on November 8, 2023

Retrieved on: 
Tuesday, October 24, 2023
Steris, NYSE, STE

DUBLIN, IRELAND, Oct. 24, 2023 (GLOBE NEWSWIRE) --  STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that it will host a conference call to discuss its fiscal 2024 second quarter financial results at 9:00 a.m.

Key Points: 
  • DUBLIN, IRELAND, Oct. 24, 2023 (GLOBE NEWSWIRE) --  STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that it will host a conference call to discuss its fiscal 2024 second quarter financial results at 9:00 a.m.
  • The conference call can be heard live at www.steris-ir.com or via phone by dialing 1-833-535-2199 in the United States or 1-412-902-6776 internationally, then asking to join the conference call for STERIS plc.
  • A press release detailing financial results will be issued after the U.S. market closes on November 7, 2023.
  • For those unable to listen to the conference call live, a replay will be available beginning at 12:00 p.m.

Cleanroom Consumables Market to grow by USD 5.31 billion from 2022 to 2027 | Rise in the adoption of cleanroom consumables in various industries to drive the growth- Technavio

Retrieved on: 
Tuesday, October 17, 2023
DuPont, Hospital, Clothing, Kimberly-Clark, Thermo Fisher Scientific, Risk, USD, Heat, Safety, Temperature, Environment, Steris, Growth, YOY, Aramark, Nature, Ventilation, Atmosphere, Risk management, Personal protective equipment, Heating, ventilation, and air conditioning

NEW YORK, Oct. 16, 2023 /PRNewswire/ -- The cleanroom consumables market will grow by USD 5.31 billion from 2022 to 2027, at a CAGR of 6.21% during the forecast period.

Key Points: 
  • NEW YORK, Oct. 16, 2023 /PRNewswire/ -- The cleanroom consumables market will grow by USD 5.31 billion from 2022 to 2027, at a CAGR of 6.21% during the forecast period.
  • Explore detailed information by purchasing a report
    The rise in the adoption of cleanroom consumables in various industries is a key factor driving market growth.
  • To preserve the quality and safety of products in various industries, clean rooms play an important role.
  • The report analyses the market size and growth and provides accurate predictions on the growth of the market.

United Medical Device Cleaning & Recycling Market Insights, 2022-2023 & 2028 Featuring Key Vendors - Steris, Getinge, ECOLAB, 3M, and Stryker - ResearchAndMarkets.com

Retrieved on: 
Friday, September 29, 2023
Recycling, Health, Medical Devices, Environment, Other Science, Science, Biotechnology, Stryker, Prevalence, Jimmy Cauty, Steris, BPH, Ageing, Houston, Disinfectant, Hospital, Getinge, Single-use medical devices, Conditional sentence, Fungal infection, Growth, Catheter-associated urinary tract infection, Medical device, Pharmaceutical industry

In the US, the medical device cleaning & recycling market was valued at $3.52 billion in 2022 and is expected to grow at a CAGR of 11.47% from 2022-2028.

Key Points: 
  • In the US, the medical device cleaning & recycling market was valued at $3.52 billion in 2022 and is expected to grow at a CAGR of 11.47% from 2022-2028.
  • This report provides valuable insights into the US medical device cleaning and recycling market, offering market size and forecast data.
  • Leading players in the medical device cleaning and recycling market include Steris, Getinge, ECOLAB, 3M, and Stryker.
  • This report provides a comprehensive and current market scenario of the US medical device cleaning & recycling market, including the US medical device cleaning & recycling market size, anticipated market forecast, relevant market segmentations, and industry trends.

The AZEK® Company Announces Peter Clifford to Take on Dual Role as Chief Operations Officer and Chief Financial Officer; Promotes Randy Herth to Chief Accounting Officer and Treasurer

Retrieved on: 
Thursday, September 28, 2023
Architecture, Residential Building & Real Estate, Manufacturing, Construction & Property, Other Manufacturing, Landscape, Information technology, Accounting, Organization, Federal Ministry of Science, Technology and Innovation, Acquisition, General Electric Company, Sri Lanka Army Medical Corps, Cantel Medical Corporation, Growth, Steris, Market for corporate control, NYSE, IDEX Corporation, Management

Mr. Clifford will also continue to serve as the Company’s Senior Vice President & Chief Financial Officer.

Key Points: 
  • Mr. Clifford will also continue to serve as the Company’s Senior Vice President & Chief Financial Officer.
  • In this new role, Mr. Clifford will assume operations oversight, while continuing to lead all finance, accounting, investor relations, information technology and corporate development functions.
  • Before joining Cantel Medical Corp., Mr. Clifford served as Chief Financial Officer – Health & Science Technologies & Fluid Metering Technology Divisions of IDEX Corporation.
  • Donnelly & Sons Company and Euramax International, Inc.
    “Randy has been a valued part of our accounting leadership team since joining AZEK in 2022,” said Peter Clifford, AZEK’s Chief Financial Officer.